Free Trial
→ SpaceX will mint billionaires. You won't be one of them. (From Behind the Markets) (Ad)tc pixel Free NMTR Stock Alerts

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo
Compare

NMTR vs. CAPS, REVB, ENSC, SXTP, and PBM

Should you buy 9 Meters Biopharma stock or one of its competitors? MarketBeat compares 9 Meters Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 9 Meters Biopharma include Capstone Therapeutics (CAPS), Revelation Biosciences (REVB), Ensysce Biosciences (ENSC), 60 Degrees Pharmaceuticals (SXTP), and Psyence Biomedical (PBM). These companies are all part of the "pharmaceutical products" industry.

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Capstone Therapeutics has higher revenue and earnings than 9 Meters Biopharma. Capstone Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.08-$21.23M-$3.37N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

9 Meters Biopharma has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-41.26% -114.15% -39.74%
9 Meters Biopharma N/A -584.97%-159.45%

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Capstone Therapeutics has a beta of -1.54, suggesting that its share price is 254% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Capstone Therapeutics had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Capstone Therapeutics and 0 mentions for 9 Meters Biopharma. Capstone Therapeutics' average media sentiment score of 0.62 beat 9 Meters Biopharma's score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Capstone Therapeutics Positive
9 Meters Biopharma Neutral

Summary

Capstone Therapeutics beats 9 Meters Biopharma on 9 of the 14 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Revelation Biosciences' return on equity of -107.65% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
9 Meters Biopharma N/A -584.97%-159.45%

Revelation Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Revelation Biosciences is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, Revelation Biosciences had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for 9 Meters Biopharma. Revelation Biosciences' average media sentiment score of 1.89 beat 9 Meters Biopharma's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Revelation Biosciences Very Positive
9 Meters Biopharma Neutral

Summary

Revelation Biosciences beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

9 Meters Biopharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. 9 Meters Biopharma's return on equity of -584.97% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-250.39% -766.45% -256.59%
9 Meters Biopharma N/A -584.97%-159.45%

Ensysce Biosciences is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce BiosciencesN/AN/A-$10.18M-$3.35N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, Ensysce Biosciences had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Ensysce Biosciences and 0 mentions for 9 Meters Biopharma. Ensysce Biosciences' average media sentiment score of 1.43 beat 9 Meters Biopharma's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Ensysce Biosciences Positive
9 Meters Biopharma Neutral

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ensysce Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Summary

9 Meters Biopharma beats Ensysce Biosciences on 7 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
9 Meters Biopharma N/A -584.97%-159.45%

60 Degrees Pharmaceuticals has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00M3.86-$7.36M-$8.92N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 849.28%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat 9 Meters Biopharma's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
9 Meters Biopharma Neutral

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 10 of the 15 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Psyence Biomedical?

9 Meters Biopharma (NASDAQ:NMTR) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Psyence Biomedical's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
Psyence Biomedical N/A N/A N/A

In the previous week, Psyence Biomedical had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Psyence Biomedical and 0 mentions for 9 Meters Biopharma. Psyence Biomedical's average media sentiment score of 1.43 beat 9 Meters Biopharma's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
9 Meters Biopharma Neutral
Psyence Biomedical Positive

9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

9 Meters Biopharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
Psyence BiomedicalN/AN/A$1.01M$25.340.13

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Given 9 Meters Biopharma's higher possible upside, research analysts plainly believe 9 Meters Biopharma is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Psyence Biomedical beats 9 Meters Biopharma on 11 of the 12 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Export
Metric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$1.04M$452.73M$6.48B$12.36B
Dividend YieldN/A3.88%2.67%5.66%
P/E Ratio0.003.1723.9524.60
Price / SalesN/A6,463.60536.37171.61
Price / CashN/A13.1327.4837.92
Price / BookN/A86.8110.446.77
Net Income-$43.77M-$96.07M$3.56B$337.32M

9 Meters Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
CAPS
Capstone Therapeutics
0.5585 of 5 stars		$0.33
+2.4%		N/A-83.5%$4.12M$48.11MN/A38
REVB
Revelation Biosciences
1.4128 of 5 stars		$1.03
-1.4%		N/A-89.5%$4.01MN/AN/A10
ENSC
Ensysce Biosciences
1.5702 of 5 stars		$0.27
+1.9%		N/A-87.9%$3.94M$5.07MN/A10
SXTP
60 Degrees Pharmaceuticals
3.2153 of 5 stars		$1.48
+1.7%		$13.85
+839.0%		-84.6%$3.92M$1.41MN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel